Entera Bio Ltd.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Entera Bio Ltd. now
Current reporting with the operating signal separated from the noise.
Entera Bio Ltd.: Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
The story matters when it changes Entera Bio Ltd.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Individual investors are Entera Bio Ltd.'s (NASDAQ:ENTX) biggest owners and were rewarded after market cap rose by US$34m last week
The story matters when it changes Entera Bio Ltd.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Entera Bio Ltd. Reports Q1 2025 Financial Results and Business Updates, Advances Oral Osteoporosis Treatment and Partnerships
The story matters when it changes Entera Bio Ltd.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates
Investors are testing whether Entera Bio Ltd.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest ENTX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Entera Bio Ltd., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →